OCLS Signs Marketing Agreement With OroScience

Oculus Innovative Sciences (OCLS) has entered into an agreement with OroScience. As per the agreement, OroScience was granted exclusive rights to market Microcyn-based oral products in the US, Canada and European professional dental and oral care markets. It would also provide Oculus with a significant percentage of those revenues.

OroScience will support all regulatory, clinical, sales and marketing related to the Microcyn-based professional oral care products, with the first product launch anticipated in 2010. The initial products will only require FDA 510(k) clearances.

Mark Fontenot, CEO of OroScience, said: “We believe our planned suite of Microcyn-based products will bring significant patient benefit for several important conditions such as oral manifestations of diabetes and oral mucositis, secondary to chemotherapy and/or radiotherapy. Our intent is to utilize our broad reach of national distribution partners to achieve timely and ubiquitous distribution.

The company has developed multiple dental-specific formulations of the Microcyn Technology (initially for the prescription market), which can also readily be translated into products for the over-the-counter oral care space.